

# Lutz Froelich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7896218/publications.pdf>

Version: 2024-02-01

281  
papers

22,666  
citations

18482

62  
h-index

10445

139  
g-index

326  
all docs

326  
docs citations

326  
times ranked

24317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global estimates on the number of persons across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2023, 19, 658-670.	0.8	146
2	Does bilingualism influence neuropsychological test performance in older adults? A systematic review. <i>Applied Neuropsychology Adult</i> , 2022, 29, 855-873.	1.2	11
3	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimer's and Dementia</i> , 2022, 18, 29-42.	0.8	24
4	Cross-cultural comparison of MMSE and RUDAS in German and Turkish patients with Alzheimer's disease. <i>Neuropsychology</i> , 2022, 36, 195-205.	1.3	6
5	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	2.8	14
6	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. <i>Brain</i> , 2022, 145, 2507-2517.	7.6	16
7	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	7.9	9
8	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	10.8	30
9	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
10	Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities. <i>JAMA Neurology</i> , 2022, 79, 633.	9.0	1
11	A Comparison of Operational Definitions for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1663-1678.	2.6	4
12	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	2.7	19
13	Crossed Cerebellar Diaschisis in Alzheimer's Disease Detected by Arterial Spin-labelling Perfusion MRI. <i>In Vivo</i> , 2021, 35, 1177-1183.	1.3	5
14	Evaluation of Sodium ( <sup>23</sup> Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. <i>In Vivo</i> , 2021, 35, 429-435.	1.3	14
15	Nicht invasive Hirnstimulation. , 2021, , 103-111.		0
16	Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 749-759.	2.6	4
17	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.8	13
18	Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline. <i>Geriatrics (Switzerland)</i> , 2021, 6, 30.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Rationale, Design, and Methodology of a Prospective Cohort Study for Coping with Behavioral and Psychological Symptoms of Dementia: The REcAge Project1. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1613-1627.	2.6	8
20	Promoting neuroplasticity and neuropsychological functioning in frailty through an app-based sensorimotor training: study protocol for a randomized trial. <i>BMC Geriatrics</i> , 2021, 21, 343.	2.7	3
21	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
22	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	3.5	9
23	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 2147-2155.	3.3	20
24	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 349-356.	1.9	31
25	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	3.2	7
26	Diagnosing foreign patients in Europe: An EADC-ISTAART study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
27	The clinical use of Alzheimer's biomarkers in patients with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
28	Is it possible to implement standard neuropsychological assessment in European memory clinics? An EADC-ISTAART survey. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
29	A rare heterozygous <i>TREM2</i> coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of <i>TREM2</i> . <i>Human Mutation</i> , 2020, 41, 169-181.	2.5	4
30	Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e73.	3.9	6
31	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 124.	6.2	12
32	Alzheimer's disease - the "microbial hypothesis" from a clinical and neuroimaging perspective. <i>Psychiatry Research - Neuroimaging</i> , 2020, 306, 111181.	1.8	16
33	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer's Disease Dementia via Lead-Lag Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1005-1015.	2.6	0
34	A European Academy of Neurology guideline on medical management issues in dementia. <i>European Journal of Neurology</i> , 2020, 27, 1805-1820.	3.3	52
35	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7
36	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Quantitative mass spectrometry suggests beta-synuclein as promising blood marker for synaptic degeneration in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040246.	0.8	0
38	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.	0.8	0
39	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	2.6	13
40	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. <i>Brain Research Bulletin</i> , 2020, 161, 13-20.	3.0	3
41	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	5.9	18
42	APOE $\epsilon$ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	6.2	28
43	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	7.7	40
44	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2020, 19, 1310-1318.	3.7	43
45	New use of psychotropic medication after hospitalization among people with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 640-649.	2.7	5
46	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 579-594.	2.6	100
47	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218111.	2.5	23
48	Case report: a giant arachnoid cyst masking Alzheimer's disease. <i>BMC Psychiatry</i> , 2019, 19, 274.	2.6	7
49	Multivariate Platelet Analysis Differentiates Between Patients with Alzheimer's Disease and Healthy Controls at First Clinical Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 993-1004.	2.6	9
50	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
51	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
52	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 164-174.	3.7	30
53	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.8	62
54	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.8	134

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.8	90
56	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
57	Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 18.	6.2	36
58	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
59	Tablet-based sensorimotor home-training system for amnesic mild cognitive impairments in the elderly: design of a randomised clinical trial. <i>BMJ Open</i> , 2019, 9, e028632.	1.9	5
60	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
61	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). <i>BMC Psychiatry</i> , 2019, 19, 423.	2.6	11
62	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 303-313.	2.6	8
63	Separating Symptomatic Alzheimer's Disease from Depression based on Structural MRI. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 353-363.	2.6	10
64	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 130.	7.4	121
65	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
66	P2-270: INCREASED CSF AMYLOID- $\beta$ 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P780.	0.8	0
67	O1-12-02: EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P249.	0.8	0
68	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P204.	0.8	0
69	P1-362: COMPARING A GERMAN VERSION OF THE FIVE WORD TEST WITH THE MINI MENTAL STATE EXAMINATION IN ITS ABILITY TO DISCRIMINATE HEALTHY CONTROLS FROM PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT AND EARLY STAGES OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P433.	0.8	0
70	P1-140: A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P328.	0.8	0
71	O1-08-05: MILD NEUROCOGNITIVE DISORDER IN DSM-5: BALANCING SENSITIVITY AND SPECIFICITY BY USING OPERATIONAL CRITERIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P237.	0.8	0
72	P1-298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID A $\beta$ 42 AND $\tau$ . <i>Alzheimer's and Dementia</i> , 2018, 14, P403.	0.8	0

#	ARTICLE	IF	CITATIONS
73	CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-5.	2.7	5
74	6. Diagnostische Methoden. , 2018, , 187-352.		0
75	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 340.	3.4	12
76	F10201: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT LIGHT AND YKL40 TO A $\beta$ 2, APOE $\epsilon$ 4 AND COGNITION: RESULTS FROM THE EMIFAD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.8	0
77	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 116.	6.2	28
78	P3003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1062.	0.8	0
79	P2038: PROBLEMS AND ISSUES OF CLINICAL SITES IN INDUSTRY SPONSORED TRIALS AND WITH CLINICAL RESEARCH ORGANIZATIONS: A EUROPEAN ALZHEIMER DISEASE CONSORTIUM (EADC) SURVEY. <i>Alzheimer's and Dementia</i> , 2018, 14, P681.	0.8	0
80	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017, 22, 153-160.	7.9	102
81	The European DTI Study on Dementia "A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017, 144, 305-308.	4.2	33
82	Late-onset major depression is associated with age-related white matter lesions in the brainstem. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 446-454.	2.7	7
83	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 939-950.	2.6	74
84	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
85	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
86	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975.	10.2	175
87	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.	2.6	24
88	[DT0202]: IDALOPIRDINE, A 5HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM. <i>Alzheimer's and Dementia</i> , 2017, 13, P1476.	0.8	0
89	[P3164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE C $\beta$ 2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P997.	0.8	0
90	[P4139]: APPLICATION OF THE A/T/N BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1310.	0.8	0

#	ARTICLE	IF	CITATIONS
91	[P1â€“275]: CONCORDANCY OF AMYLOIDâ€“BETAâ€“1â€“42 IN CSF AND [18F]FLORBETABENâ€“PET IN CLINICAL PRACTISE OF A MEMORY CLINIC. Alzheimer's and Dementia, 2017, 13, P355.	0.8	0
92	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.8	3
93	[P2â€“194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.8	0
94	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	6.2	58
95	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
96	Development of a Proxy-Free Objective Assessment Tool of Instrumental Activities of Daily Living in Mild Cognitive Impairment Using Smart Home Technologies. Journal of Alzheimer's Disease, 2016, 52, 509-517.	2.6	32
97	P4â€“122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0
98	P1â€“056: Idalopirdine, A 5â€“HT6 Antagonist in Phase III Development as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mildâ€“toâ€“Moderate Alzheimerâ€™s Disease: Baseline Data from the Ongoing Starshine Study. Alzheimer's and Dementia, 2016, 12, P423.	0.8	0
99	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics, 2016, 8, 593-598.	2.1	5
100	Electroconvulsive therapy selectively enhances amyloid Î² 1â€“42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology, 2016, 26, 1877-1884.	0.7	20
101	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	2.6	18
102	Drug development in Alzheimerâ€™s disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	6.2	323
103	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.8	50
104	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179
105	Impaired and preserved aspects of feedback learning in aMCI: contributions of structural connectivity. Brain Structure and Function, 2016, 221, 2831-2846.	2.3	18
106	P4-273: Using neuropsychological criteria to distinguish between memory clinic patients with subjective cognitive decline and MCI. , 2015, 11, P889-P890.		0
107	A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. Journal of the American Medical Directors Association, 2015, 16, 1104.e1-1104.e7.	2.5	12
108	The Latent Dementia Phenotype Î´ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 547-560.	2.6	23



#	ARTICLE	IF	CITATIONS
109	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015, 12, 69-79.	1.4	22
110	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
111	O2-02-04: The latent dementia phenotype is associated with the CSF Alzheimer's disease biomarker signature in subjects with mild cognitive impairment. , 2015, 11, P176-P176.		0
112	Combined treatment with memantine and galantamine compared with galantamine only in antedementia drug naïve patients with mild to moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 198-204.	3.7	25
113	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	3.1	125
114	Editorial: Siegfried Hoyer's concept of Alzheimer pathophysiology. <i>Journal of Neural Transmission</i> , 2015, 122, 495-497.	2.8	2
115	The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy. <i>Journal of Neural Transmission</i> , 2015, 122, 499-504.	2.8	33
116	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
117	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.1	41
118	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 166-177.	2.7	13
119	Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 9.	6.2	8
120	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 17.	6.2	419
121	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
122	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 27.	6.2	13
123	Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 332-347.	1.5	37
124	Out-of-Home Behavior and Cognitive Impairment in Older Adults. <i>Journal of Applied Gerontology</i> , 2015, 34, 3-25.	2.0	70
125	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	27.8	58
126	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7.	2.4	23



#	ARTICLE	IF	CITATIONS
127	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
128	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. <i>PLoS ONE</i> , 2014, 9, e100812.	2.5	41
129	Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT. <i>Frontiers in Psychiatry</i> , 2014, 5, 22.	2.6	77
130	SUCLG2 identified as both a determinant of CSF A $\beta$ 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	2.9	45
131	Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 121-128.	2.7	18
132	“Dementia worry” in memory clinic patients not diagnosed with organic mental disorder. <i>International Psychogeriatrics</i> , 2014, 26, 1049-1051.	1.0	25
133	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53.	10.8	216
134	Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. <i>Neuroscience Letters</i> , 2014, 561, 41-45.	2.1	33
135	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. , 2014, 10, e27-e39.		9
136	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34
137	Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 507-523.	2.1	38
138	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014, 10, 456-467.	0.8	16
139	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S269-76.	0.8	47
140	Severe agitation in severe early-onset Alzheimer's disease resolves with ECT. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2147.	2.2	14
141	P1-046: ROLE OF PLD3 RARE VARIANTS IN EUROPEAN SPORADIC ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P319-P320.		0
142	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0
143	C0303: Prospective Controlled Study to Identify the Preference of Patients for a Conventional Or Direct Oral Anticoagulant Using a Short Questionnaire. <i>Thrombosis Research</i> , 2014, 133, S17.	1.7	12
144	P4-192: CEREBROLYSIN IN MILD TO MODERATE ALZHEIMER'S DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS. , 2014, 10, P859-P859.		3

#	ARTICLE	IF	CITATIONS
145	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15097-15102.	7.1	50
146	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	3.1	86
147	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. Neurology, 2013, 80, 1124-1132.	1.1	110
148	The Association Between APOE $\epsilon$ 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
149	Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 583-591.	1.9	12
150	Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	1.5	41
151	Comparison of Visual Evoked Potentials and Retinal Nerve Fiber Layer Thickness in Alzheimer's Disease. Frontiers in Neurology, 2013, 4, 203.	2.4	21
152	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 389-401.	2.6	13
153	A combined electrophysiological and morphological examination of episodic memory decline in amnesic mild cognitive impairment. Frontiers in Aging Neuroscience, 2013, 5, 51.	3.4	12
154	Using Voxel-Based Morphometry to Examine the Relationship between Regional Brain Volumes and Memory Performance in Amnesic Mild Cognitive Impairment. Frontiers in Behavioral Neuroscience, 2013, 7, 89.	2.0	21
155	Risk Factors for Hypovitaminosis D in Gerontopsychiatric Patients. primary care companion for CNS disorders, The, 2013, 15, .	0.6	0
156	CORDIAL. Alzheimer Disease and Associated Disorders, 2012, 26, 246-253.	1.3	96
157	Pharmacological treatment of dementia. Current Opinion in Psychiatry, 2012, 25, 542-550.	6.3	55
158	Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm <sup>2</sup> ) in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 341-353.	1.5	88
159	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology, 2012, 78, 379-386.	1.1	141
160	A Polymorphic Microsatellite Repeat within the ECE-1c Promoter Is Involved in Transcriptional Start Site Determination, Human Evolution, and Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16807-16820.	3.6	17
161	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 2012, 9, 902-912.	1.4	42
162	The Role of Variation at $\epsilon$ 2PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53

#	ARTICLE	IF	CITATIONS
163	Dementia worry: a psychological examination of an unexplored phenomenon. <i>European Journal of Ageing</i> , 2012, 9, 275-284.	2.8	152
164	C0134 Internet based questionnaire for the analysis of preference of patients for anticoagulants. <i>Thrombosis Research</i> , 2012, 130, S190.	1.7	0
165	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. <i>Neurobiology of Aging</i> , 2012, 33, 201.e1-201.e8.	3.1	48
166	A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 544-548.	3.3	48
167	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 2-32.	2.6	77
168	The future of Alzheimer's disease: The next 10 years. <i>Progress in Neurobiology</i> , 2011, 95, 718-728.	5.7	190
169	Cholinesterase inhibitor treatment in patients with delirium. <i>Lancet, The</i> , 2011, 377, 899.	13.7	4
170	Phenserine Efficacy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1201-1208.	2.6	62
171	Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 363-374.	2.6	59
172	Should electroconvulsive therapy be more routinely used in the treatment of depression in elderly patients with cognitive disturbances?. <i>Neuropsychiatry</i> , 2011, 1, 403-407.	0.4	1
173	Association of N-Acetylaspartate and Cerebrospinal Fluid A $\beta$ 242 in Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 393-399.	2.6	10
174	Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 255-262.	2.6	29
175	Do Instrumental Activities of Daily Living Predict Dementia at 1â€•and 2â€•Year Followâ€•Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer's Disease Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2273-2281.	2.6	59
176	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
177	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 109-113.	2.6	8
178	Regional Differences in Effects of APOE $\epsilon$ 4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.	1.5	18
179	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2011, 8, 893-901.	1.4	27
180	Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) in Depressed Elderly Inpatients With Coexisting Mild Cognitive Impairment or Dementia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 91-97.	2.2	98

#	ARTICLE	IF	CITATIONS
181	Consensus statement on dementia education and training in Europe. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 131-135.	3.3	31
182	Assessing physician attitudes and perceptions of Alzheimer's disease across Europe. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 537-544.	3.3	17
183	Two cases of primary hyperparathyroidism with depressive and cognitive symptoms. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 798-799.	3.3	3
184	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 244-250.	1.8	46
185	Turning principles into practice in Alzheimer's disease. <i>International Journal of Clinical Practice</i> , 2010, 64, 1198-1209.	1.7	5
186	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	7.9	156
187	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	2.5	347
188	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 155-165.	2.6	10
189	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 246-253.	3.9	25
190	Amyloid $\beta$ peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. <i>Experimental Neurology</i> , 2010, 223, 366-370.	4.1	92
191	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 235-270.	2.6	42
192	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	1.5	90
193	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1069-1074.	1.9	39
194	Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey. <i>Current Medical Research and Opinion</i> , 2009, 25, 3059-3068.	1.9	24
195	A multicenter <sup>1</sup> H-MRS study of the medial temporal lobe in AD and MCI. <i>Neurology</i> , 2009, 72, 1735-1740.	1.1	72
196	Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 613-622.	2.6	18
197	Conversion to dementia in mild cognitive impairment is associated with decline of N-acetylaspartate and creatine as revealed by magnetic resonance spectroscopy. <i>Psychiatry Research - Neuroimaging</i> , 2009, 173, 1-7.	1.8	52
198	Quality of Life as an outcome in Alzheimer's disease and other dementias- obstacles and goals. <i>BMC Neurology</i> , 2009, 9, 47.	1.8	27

#	ARTICLE	IF	CITATIONS
199	Association of SORL1 gene variants with Alzheimer's disease. Brain Research, 2009, 1264, 1-6.	2.2	49
200	Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurology, The, 2009, 8, 39-47.	10.2	137
201	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
202	Risk of Incident Alzheimer's Disease in Diabetic Patients: A Systematic Review of Prospective Trials. Journal of Alzheimer's Disease, 2009, 16, 677-685.	2.6	208
203	Safety and Tolerability of the Rivastigmine Patch. Alzheimer Disease and Associated Disorders, 2009, 23, 158-164.	1.3	39
204	Lithium Trial in Alzheimer's Disease. Journal of Clinical Psychiatry, 2009, 70, 922-931.	2.2	252
205	Use of alternative therapies in patients with dementia and mild cognitive impairment: a prospective, controlled study. International Journal of Geriatric Psychiatry, 2008, 23, 1163-1165.	2.7	14
206	Influence of SORL1 gene variants: Association with CSF amyloid- $\beta^2$ products in probable Alzheimer's disease. Neuroscience Letters, 2008, 440, 68-71.	2.1	43
207	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease &ndash; Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	1.5	8
208	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. Neuroepidemiology, 2008, 30, 254-265.	2.3	86
209	Diagnostic Accuracy of the Clock Drawing Test: The Relevance of "Time Setting" in Screening for Dementia. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 250-260.	2.3	16
210	IDEAL. Neurology, 2007, 69, S14-22.	1.1	167
211	Commentary on "Health economics and the value of therapy in Alzheimer's disease." Value therapy for Alzheimer's disease-A European perspective. , 2007, 3, 152-156.		3
212	AIDS dementia complex and Hashimoto encephalopathy in a senescent woman. International Journal of Geriatric Psychiatry, 2007, 22, 1267-1268.	2.7	3
213	Amyloid $\beta^2$ peptide ratio 42/40 but not $A\beta^{242}$ correlates with phospho $\tau$ in patients with low and high CSF $A\beta^{240}$ load. Journal of Neurochemistry, 2007, 101, 1053-1059.	3.9	237
214	Increased T-cell Reactivity and Elevated Levels of CD8+ Memory T-cells in Alzheimer's Disease-patients and T-cell Hyporeactivity in an Alzheimer's Disease-mouse Model: Implications for Immunotherapy. NeuroMolecular Medicine, 2007, 9, 340-354.	3.4	42
215	Brain imaging and neuropsychology in late-onset dementia due to a novel mutation (R93C) of valosin-containing protein. , 2007, 26, 232-240.		25
216	Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects. Journal of Nutrition, Health and Aging, 2007, 11, 357-8.	3.3	2

#	ARTICLE	IF	CITATIONS
217	Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 38-41.	3.1	73
218	Apoptosis of CD4+ T and Natural Killer Cells in Alzheimer's Disease. <i>Pharmacopsychiatry</i> , 2006, 39, 220-228.	3.3	41
219	Occupational exposure to low frequency magnetic fields and dementia: a case-control study. <i>Occupational and Environmental Medicine</i> , 2006, 64, 108-114.	2.8	24
220	Realistic expectations for treatment success in Alzheimer's disease. <i>Journal of Nutrition, Health and Aging</i> , 2006, 10, 417-29.	3.3	54
221	The practice of obtaining approval from medical research ethics committees: a comparison within 12 European countries for a descriptive study on acetylcholinesterase inhibitors in Alzheimer's dementia. <i>European Journal of Neurology</i> , 2005, 12, 212-217.	3.3	36
222	The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 645-650.	2.7	42
223	Enhanced ROS-Generation in Lymphocytes from Alzheimer's Patients. <i>Pharmacopsychiatry</i> , 2005, 38, 312-315.	3.3	47
224	Diagnostic Value of FDG-PET and HMPAO-SPET in Patients with Mild Dementia and Mild Cognitive Impairment: Metabolic Index and Perfusion Index. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 63-70.	1.5	42
225	Memory for Performed Actions in Dementia of Alzheimer Type: Further Evidence for a Global Semantic Memory Deficit. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 381-387.	1.5	8
226	Longitudinal Study on the Relationship Between Symptomatology of Dementia and Levels of Subjective Burden and Depression Among Family Caregivers in Memory Clinic Patients. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 119-128.	2.3	95
227	Nicotine use in suicides: a case-control study. <i>European Psychiatry</i> , 2005, 20, 129-136.	0.2	31
228	Intravenous immunoglobulins containing antibodies against $\text{A}\beta$ -amyloid for the treatment of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1472-1474.	1.9	300
229	Psychosocial work factors and dementia. <i>Occupational and Environmental Medicine</i> , 2004, 61, 962-971.	2.8	61
230	The Fuzzy Frontier between Subjective Memory Complaints and Early Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 222-230.	1.5	7
231	(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia. <i>Journal of Neural Transmission</i> , 2004, 111, 295-310.	2.8	24
232	Impairment of Gs $\beta$ function in human brain cortex of Alzheimer's disease: comparison with normal aging. <i>Journal of Neural Transmission</i> , 2004, 111, 311-322.	2.8	17
233	No effects of a combination of caregivers support group and memory training/music therapy in dementia patients from a memory clinic population. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 223-231.	2.7	45
234	Combination Therapy in Alzheimer's Disease. <i>CNS Drugs</i> , 2004, 18, 827-844.	5.9	152



#	ARTICLE	IF	CITATIONS
235	Concordance of DSM-IV Axis I and II diagnoses by personal and informant's interview. <i>Psychiatry Research</i> , 2004, 127, 121-136.	3.3	91
236	Impact of Aging: Sporadic, and Genetic Risk Factors on Vulnerability to Apoptosis in Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2003, 4, 161-178.	3.4	30
237	Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. <i>Psychiatry Research - Neuroimaging</i> , 2003, 123, 183-190.	1.8	41
238	Association between the psychosocial network and dementia—a case-control study. <i>Journal of Psychiatric Research</i> , 2003, 37, 89-98.	3.1	33
239	Olfactory Function in Mild Cognitive Impairment and Alzheimer's Disease: An Investigation Using Psychophysical and Electrophysiological Techniques. <i>American Journal of Psychiatry</i> , 2003, 160, 1995-2002.	7.2	152
240	An Observational Clinical Study of the Efficacy and Tolerability of Donepezil in the Treatment of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 189-198.	1.5	21
241	Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET. <i>NeuroImage</i> , 2002, 17, 302-316.	4.2	714
242	Functional Imaging of Visuospatial Processing in Alzheimer's Disease. <i>NeuroImage</i> , 2002, 17, 1403-1414.	4.2	185
243	Psychometric properties of Clock Drawing Test and MMSE or Short Performance Test (SKT) in dementia screening in a memory clinic population. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 254-260.	2.7	81
244	A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1999, 893, 290-293.	3.8	147
245	Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. <i>Neuroscience Letters</i> , 1999, 263, 161-164.	2.1	96
246	Postnatal ontogeny of GTP binding protein in the human frontal cortex. <i>Life Sciences</i> , 1999, 65, 2315-2323.	4.3	5
247	Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. <i>Phytomedicine</i> , 1998, 5, 417-424.	5.3	7
248	Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. <i>Journal of Neural Transmission</i> , 1998, 105, 423.	2.8	658
249	Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type. <i>Journal of Neural Transmission</i> , 1998, 105, 961-973.	2.8	20
250	Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. <i>Psychiatry Research - Neuroimaging</i> , 1998, 84, 27-35.	1.8	26
251	Increase of optical illusion in demented patients. <i>Journal of Neural Transmission Supplementum</i> , 1998, 54, 61-67.	0.5	0
252	Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. <i>Journal of Psychiatric Research</i> , 1997, 31, 645-655.	3.1	191



#	ARTICLE	IF	CITATIONS
253	A comparison of gEEG and HMPAO-SPECT in relation to the clinical severity of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 259-263.	3.2	20
254	Left hemispheric reductions of regional cerebral blood flow (rCBF) correlate with measures of dementia severity in patients with Alzheimer's disease: a SPECT study. European Psychiatry, 1996, 11, 314-318.	0.2	4
255	Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biological Psychiatry, 1996, 39, 319-325.	1.3	44
256	Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sciences, 1996, 60, 13-19.	4.3	43
257	Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type. NeuroReport, 1996, 7, 2965-2970.	1.2	37
258	Investigations on the Point Mutations at nt 5460 of the mtDNA in Different Neurodegenerative and Neuromuscular Diseases. European Neurology, 1996, 36, 149-153.	1.4	17
259	Alteration of Glutamyltranspeptidase Binding Proteins in Postmortem Brains of Heroin Addicts. Alcoholism: Clinical and Experimental Research, 1996, 20, 301A-304A.	2.4	17
260	Alteration of Glutamyltranspeptidase Binding Proteins in Postmortem Brains of Heroin Addicts. Alcoholism: Clinical and Experimental Research, 1996, 20, 301A-304A.	2.4	1
261	Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. Journal of Neural Transmission, 1995, 99, 55-62.	2.8	26
262	Decline and preservation of reversal learning abilities and acquisition in the course of senescence. Neuroscience Letters, 1995, 194, 121-123.	2.1	9
263	Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type. Journal of Neurochemistry, 1995, 64, 1216-1223.	3.9	149
264	Quantity and Quality Changes of G Protein in Dementia of the Alzheimer Type. Advances in Behavioral Biology, 1995, , 291-296.	0.2	2
265	Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung, 1995, 45, 443-6.	0.4	35
266	Event-Related Potentials and Psychopharmacology. Pharmacopsychiatry, 1994, 27, 72-74.	3.3	57
267	Effects of long-term recovery from transient cerebral ischemia in rat brain: Tissue levels of acetylcholine, monoamines, and their metabolites. Neurochemical Research, 1993, 18, 1239-1244.	3.3	7
268	Imbalance of the Gs and Gi/o function in post-mortem human brain of depressed patients. Journal of Neural Transmission, 1993, 94, 63-69.	2.8	39
269	Alterations of guanine nucleotide-binding proteins in post-mortem human brain in alcoholics. Brain Research, 1993, 620, 174-179.	2.2	36
270	Segmentation of the Spontaneous EEG in Dementia of the Alzheimer Type. Neuropsychobiology, 1993, 27, 231-236.	1.9	30

#	ARTICLE	IF	CITATIONS
271	Dementia of the Alzheimer type: effects on the spontaneous EEG described by dipole sources. <i>Psychiatry Research</i> , 1993, 50, 151-162.	3.3	3
272	Susceptibility of Brains from Patients with Alzheimer's Disease to Oxygen-Stimulated Lipid Peroxidation and Differential Scanning Calorimetry. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992, 3, 213-222.	1.5	7
273	DIAGNOSTIC VALUE OF HMPAO-SPECT AND TOPOGRAPHIC ANALYSIS OF EEG IN DEMENTIA OF ALZHEIMER TYPE.. <i>Clinical Neuropharmacology</i> , 1992, 15, 192A-193A.	0.7	1
274	Differential validity of psychometric tests in dementia of the Alzheimer type. <i>Psychiatry Research</i> , 1992, 44, 93-106.	3.3	123
275	Topography of the quantitative electroencephalogram in dementia of the alzheimer type: Relation to severity of dementia. <i>Psychiatry Research - Neuroimaging</i> , 1991, 40, 181-194.	1.8	76
276	Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1991, 240, 363-366.	0.9	53
277	Changes in pyruvate dehydrogenase complex (PDHc) activity and [3H]QNB-receptor binding in rat brain subsequent to intracerebroventricular injection of bromopyruvate. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1990, 2, 169-178.	1.2	8
278	Glucocorticoid receptors on mononuclear leukocytes in Alzheimer's disease. <i>Psychiatry Research</i> , 1990, 34, 237-241.	3.3	8
279	Dementia and stroke: Biology of the aging brain. <i>Neurobiology of Aging</i> , 1987, 8, 179-184.	3.1	2
280	First results on the effect of vincristine on brain glucose and energy metabolism in rats. <i>Mechanisms of Ageing and Development</i> , 1980, 14, 223-231.	4.6	3
281	Influence of a Memory Training Program on Attention and Memory Performance of Patients with Dementia. , 0, , 821-831.		2